

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

## Xolair® (omalizumab) Standard Plan of Treatment for Nasal Polyps

### PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:				
Patient Name:	Address:				
Date of Birth:	City, State, Zip:				
Height in inches:	Weight: LB or KG	Gender:	Allergies:	See list	NKDA

### DIAGNOSIS: (PLEASE COMPLETE 2<sup>ND</sup> AND 3<sup>RD</sup> DIGITS TO COMPLETE ICD 10 FOR BILLING)

J33.0 - Polyp of nasal cavity	J33.1 - Polypoid sinus degeneration
J33.8 - Other polyp of sinus	J33.9 - Nasal polyp, unspecified
_____ - Other:	

### REQUESTED DOCUMENTATION:

1	Insurance information	IF NO:	IF YES:
2	Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3	Full medication list	REQUIRED WASHOUT	NEXT INFUSION DATE:
4	Tried and failed therapies	FROM PREVIOUS	<b>IF ORDER CHANGE:</b>
5	Pre-treatment serum IgE level as required for pretreatment dosing	THERAPY:	<b>Continue current order until insurance approved</b>

### Provider Attestation for HCP administration:

<input type="checkbox"/> Provider attests that the patient or caregiver is not competent or is physically unable to administer the Xolair labeled self-administration.	<input type="checkbox"/> The location and circumstances for self-administration are not adequate for the potential treatment of anaphylaxis should that arise.
<input type="checkbox"/> Patient has experienced severe hypersensitivity reactions to Xolair or other agents, such as foods, drugs, biologics, within the past 6 months or requires administration and direct monitoring by a healthcare professional.	<input type="checkbox"/> Patient has a history of uncontrolled disease and ordering physician attests that in their clinical opinion, it is not advisable to try the self-administration formulation of requested drug
<input type="checkbox"/> Patient has not received at least 3 doses of Xolair under the guidance of a healthcare provider with no hypersensitivity reactions*	<input type="checkbox"/> Due to patient's weight, ordering provider attests that in their clinical opinion, it is not advisable to try the self-administered formulation of requested drug.

\*Specific reactions: \_\_\_\_\_

### MEDICATION ORDERS:

**NOTE: Patient may be ineligible to receive Xolair® (omalizumab) if patient has signs/symptoms of parasitic infection, is currently being treated for a parasitic infection, or is having acute bronchospasm and/or asthma attack.**

### MEDICATION/FREQUENCY:

Xolair® (omalizumab) subcutaneously every 2 weeks:  Xolair® (omalizumab) subcutaneously every 4 weeks:

### DOSE:

75mg/dose  150 mg/dose  225mg/dose  300mg/dose  375mg/dose  450mg/dose  
 525mg/dose  600mg/dose

**Administer as subcutaneous injection to upper arm, thigh, or abdomen. No more than 150 mg per injection site**

### SPECIAL ORDERS:

Extended post treatment monitoring for any patient new to therapy: monitor patient for two (2) hours after first 3 injections, and for 30-minutes after all subsequent injections.

Refills x 12 months unless noted otherwise here:

### CARE ORDERS:

Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated

### ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



### PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

### PRESCRIBER SIGNATURE: (No stamp signatures)

DATE

Dispense as written/Brand medically necessary	Substitution permitted
---	------------------------



## Checklist for referrals to Palmetto Infusion: Fax referral to 1.800.521.9640

- Patient demographics - address, phone number, SS#, etc.**
- Insurance information - copy of the card(s) if possible**
- Plan of Treatment/Orders**
- Most recent physician office notes to include tried and failed therapies - all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs.**
- Any lab results or other diagnostic procedures to support the diagnosis.**

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for your referral.

[www.PalmettoInfusion.com](http://www.PalmettoInfusion.com)